Trials / Recruiting
RecruitingNCT05865301
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 26 Years
- Healthy volunteers
- Not accepted
Summary
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Questionnaire for patients receiving therapy | Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion. |
Timeline
- Start date
- 2023-06-29
- Primary completion
- 2026-04-30
- Completion
- 2038-12-31
- First posted
- 2023-05-18
- Last updated
- 2026-02-09
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05865301. Inclusion in this directory is not an endorsement.